Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALY688 in Dry Eye Disease
NCT04899518Phase 3Completed
- Sponsor
- Allysta Pharmaceuticals
- Start
- May 2021
- Primary completion
- Mar 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of ALY688 in dry eye disease (DED), sponsored by Allysta Pharmaceuticals. Started May 2021; status: completed.
02
Drugs
ALY688
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04899518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899518.